Emerg Infect Dis. 2020 Jun;26(6):1266-1273. doi: 10.3201/eid2606.200516. Epub 2020 Jun 17.
The etiologic agent of an outbreak of pneumonia in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 in January 2020. A patient in the United States was given a diagnosis of infection with this virus by the state of Washington and the US Centers for Disease Control and Prevention on January 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens from this patient and characterized the viral sequence, replication properties, and cell culture tropism. We found that the virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into 2 virus repositories, making it broadly available to the public health and research communities. We hope that open access to this reagent will expedite development of medical countermeasures.
2020 年 1 月，中国武汉肺炎疫情的病原体被确定为严重急性呼吸综合征冠状病毒 2 型。2020 年 1 月 20 日，美国华盛顿州和美国疾病控制与预防中心诊断该州一名患者感染了这种病毒。我们从该患者的鼻咽和口咽标本中分离出病毒，并对其病毒序列、复制特性和细胞培养嗜性进行了鉴定。我们发现，该病毒在无胰蛋白酶存在的情况下，可在 Vero-CCL81 细胞和 Vero E6 细胞中高效复制。我们还将病毒存入了 2 个病毒库，使其广泛提供给公共卫生和研究界。我们希望公开获取该试剂，将加快医疗对策的开发。
